Table 1. Model Parameter Values: Epidemiology and Cohort Assumptions.^* .

	Base	Min	Max	Source
Proportion of F0 patients who are non-progressors	0.2420	0.0960	0.7410	[10]
6 months transition probabilities relating to fibrosis progression				[10], [16]
Remission (from F0)	0.0060	0.0035	0.0085
F4 to decompensated cirrhosis (DC)	0.0198	0.0159	0.0247
Cirrhosis (both F4 and DC) to HCC	0.0104	0.0085	0.0139
Progression, men by age				[10], [16]
40–49	0.0266	0.0134	0.0464
50–59	0.0606	0.0358	0.0773
60–69	0.1046	0.0606	0.1601
≥70	0.1397	0.0732	0.2126
Progression, women by age				[10], [16]
40–49	0.0139	0.0065	0.0286
50–59	0.0320	0.0139	0.0564
60–69	0.0554	0.0208	0.1113
70–79	0.0741	0.0397	0.1298
≥80	0.0997	0.0416	0.1626
Liver transplant 6 month probability				[49]
Liver transplant from DC	0.0253	0	0.2254
Liver transplant from HCC	0.0780	0.0253	0.2254
Disease mortality (6 month rate)
Liver transplant mortality	0.0760	0.0719	0.0807	[50]
Post liver transplant mortality	0.0256	0.0250	0.0260	[50]
Decompensated cirrhosis mortality	0.1530	0.0645	0.1975	[10]
HCC mortality	0.2165	0.1595	0.2495	[10]
Liver biopsy mortality (use as probability)	0.0003	0	0.0033	[51]
Treatment mortality (annual rate)	0.0005	0.00025	0.0008	[52]
Cohort starting agea	40	40	70	Assumed
Discount rate (annual)	0.03	0	0.05	[7]

*All references included in Table 1– 3 are from published literature unless explicitly stated as our assumptions.

^aWe run the same model with cohorts at different starting age to identify the most cost-effective strategy at each age.